The present invention provides an immune enhancer comprising at least an interferon and a granulocyte-macrophage colony-stimulating factor, and an immunotherapeutic pharmaceutical composition comprising at least an antigen and the above-mentioned immune enhancers. The present invention further discloses a preparation method of the immunotherapeutic pharmaceutical composition, the use of the immune enhancer and the immunotherapeutic pharmaceutical composition. The immune enhancer can be applied to disease and tumor treatments caused by viruses, bacteria, and other microorganisms.

Provided is a method for preparation of a composition comprising activated human CD8.sup.+ and natural killer (NK) lymphocytes. The method entails use of mature dendritic cells as feeder cells added at an early stage in CD4.sup.+ mediated activation of the CD8.sup.+ cells. Also provided is a method for treatment of cancer using the cells obtained from the process.

This invention provides methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, by administering a combination of WT1 peptides including each of: YMFPNAPYL, RSDELVRHHNMHQRNMTKL, PGCNKRYFKLSHLQMHSRKHTG, SGQAYMFPNAPYLPSCLES, NLMNLGATL, WNLMNLGATLKGVAA, and WNYMNLGATLKGVAA, or cytotoxic T cells induced by the combination of WT1 peptides. The combination of WT1 peptides may be administered to the subject via a WT1 delivery agent, i.e., in peptide form, or in the form of nucleic acids encoding the WT1 peptides, or in the form of immune cells comprising nucleic acids encoding the WT1 peptides, and/or comprising or presenting the WT1 peptides. The WT1 delivery agents or CTLs can be administered to the subject in a single composition (as a heptavalent immunotherapy composition), or multiple compositions, resulting in delivery of all seven WT1 peptides and induction of an immune response against the WT1-expressing cancer.

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

The invention provides novel compositions, methods, and therapeutic uses related to fusogenic protein MINION (microprotein inducer of fusion).

The present application provides methods of preparing tumor antigen-specific T cells comprising enriching activated T cells from a first co-culture comprising a first population of antigen-loaded dendritic cells loaded and a population of T cells, and co-culturing the enriched activated T cells with a second population of antigen-loaded dendritic cells. Also provided are methods of treating cancer in an individual using the tumor antigen-specific T cells, pharmaceutical compositions and kits for cell-based cancer immunotherapy.

The disclosure relates to anti-ALPP CAR-T cell therapies for the treatment of cancer patients having ALPP-positive cancer, including e.g., ovarian, endometrial, cervical, testicular cancers, etc.

Provided herein are constructs comprising a CAR nucleic acid sequence comprising a single chain variable fragment from monoclonal antibody VAC69 for use in stimulating an immune response against solid tumors. The CAR nucleic acid sequence is linked to nucleic acids encoding one or more cytokines, and one or more of a matrix metalloprotease, a PD1 fusion protein, a chemokine receptor, a dominant negative or nonfunctional immunosuppressive or toxic receptor, a FOXP3 inhibitory peptide P60, and a Bi-specific T Cell Engager (BiTE). The constructs can further include one or more of a signal peptide, a self-cleaving peptide, an epitope tag, an internal ribosome entry site (IRES), or a selectable marker.

The present invention includes methods and compositions for treating cancer, whether a solid tumor or a hematologic malignancy. By expressing a chimeric antigen receptor in a monocyte, macrophage or dendritic cell, the modified cell is recruited to the tumor microenvironment where it acts as a potent immune effector by infiltrating the tumor and killing the target cells. One aspect includes a modified cell and pharmaceutical compositions comprising the modified cell for adoptive cell therapy and treating a disease or condition associated with immunosuppression.

The present disclosure provides methods for treating a progressive ovarian cancer using an allogeneic leukemia-derived cell. Also provided are immunogenic compositions comprising an allogeneic leukemia-derived cell, and pharmaceutical compositions and formulations thereof.